Remove Aging and mental health Remove Healthcare Remove Manufacturing
article thumbnail

In Brain Chemistry We Trust—The Gospel According to Pharma

Mad in America

What began as a wonderful career combining my scientific knowledge with creative writing gradually revealed itself as something far more troubling: I was helping to manufacture “facts” about diseases and treatments that would shape medical practice for decades. reporting receiving treatment for depression in 2023.The

article thumbnail

FDA Requires New Label Warning of Weight Loss Risk in Pediatric Patients Taking Extended-Release Stimulants for ADHD

Psychiatric Times

Healthcare professionals should monitor weight and growth in young patients on these medications and consider alternative treatments if adverse effects occur. SHOW MORE The FDA will update ADHD medication labels, warning of weight loss risks in children under 6, urging careful monitoring by health care professionals.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Antidepressant Use Linked to Sexual Dysfunction, Why Aren’t Prescribers Discussing It?

Mad in America

What’s concerning is that despite the significant impact of sexual dysfunction on patients’ quality of life, many did not discuss these issues with their healthcare providers. at the time of the study, indicating affiliations with pharmaceutical companies that manufacture antidepressants, including those under investigation.

article thumbnail

Critical Psychiatry Textbook, Chapter 16: Is There Any Future for Psychiatry? (Part Six)

Mad in America

In 1990-92, 12% of the US population aged 18–54 years received treatment for emotional problems, which went up to 20% in 2001–2003. In 1990-92, 12% of the US population aged 18–54 years received treatment for emotional problems, which went up to 20% in 2001–2003. Talk about mental health instead. 695 This is sickening.

article thumbnail

Branding Diseases—How Drug Companies Market Psychiatric Conditions: An Interview with Ray Moynihan

Mad in America

R ay Moynihan is an accomplished health journalist and author who has won several awards for his work. Moynihan’s research and writing focus on the healthcare industry, with an emphasis on how diseases are created, branded, and marketed to unsuspecting people. This applies in the mental illness world and everywhere in medicine.

article thumbnail

Medication Overload, Part II: The Explosion of Drugs for Kids

Mad in America

I n the early 1960s, around the age of two, I experienced an accidental overdose. The incident occurred after one of my preschool-age siblings managed to use a kitchen chair to retrieve the tasty but very toxic medicine, open the bottle, and then give it to me believing the “candy medicine” would help their baby sister feel better.

article thumbnail

Upcoming ECT Legislation Needs to Be Revised

Mad in America

McCarthy Vahey , and distinguished members of the Connecticut Public Health Committee : I am sharing the following information related to H.B. ECT is a psychiatric treatment for clinical depression and other mental health conditions in which electrical impulses are passed through a persons brain to cause brief seizures (Egan, 2018).